Advertisement
U.S. Markets open in 4 hrs 44 mins

Mainz Biomed N.V. (MYNZ)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.2387-0.0113 (-4.52%)
At close: 04:00PM EST
0.2200 -0.02 (-7.83%)
Pre-Market: 04:26AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.2500
Open0.2480
Bid0.2295 x 1300
Ask0.2389 x 100
Day's Range0.2295 - 0.2485
52 Week Range0.1850 - 1.7900
Volume2,725,844
Avg. Volume3,167,267
Market Cap15.287M
Beta (5Y Monthly)0.08
PE Ratio (TTM)N/A
EPS (TTM)-1.1100
Earnings DateNov 14, 2024 - Nov 15, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
  • Benzinga

    The Oncology Bet Is Already Paying Off For Pfizer

    With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs.

  • GlobeNewswire

    Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

    BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation (“Thermo Fisher”), a world leader in supplying life sciences solutions and services. The collaboration agreement will enable Mainz B